NRx Pharmaceuticals’ (NRXP) Buy Rating Reaffirmed at D. Boral Capital

NRx Pharmaceuticals (NASDAQ:NRXP)‘s stock had its “buy” rating reiterated by investment analysts at D. Boral Capital in a report issued on Tuesday,Benzinga reports. They currently have a $34.00 price objective on the stock.

Several other equities analysts have also recently commented on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of NRx Pharmaceuticals in a research report on Monday, December 29th. BTIG Research reaffirmed a “buy” rating and set a $25.00 price target on shares of NRx Pharmaceuticals in a research report on Tuesday. Ascendiant Capital Markets reiterated a “buy” rating and set a $48.00 price target (up from $47.00) on shares of NRx Pharmaceuticals in a report on Friday, January 2nd. HC Wainwright boosted their price objective on NRx Pharmaceuticals from $40.00 to $45.00 and gave the stock a “buy” rating in a research report on Tuesday, March 3rd. Finally, Zacks Research upgraded NRx Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, March 2nd. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $38.00.

NRx Pharmaceuticals Stock Performance

NRXP traded up $0.32 during mid-day trading on Tuesday, reaching $2.09. 1,164,907 shares of the stock were exchanged, compared to its average volume of 1,054,915. NRx Pharmaceuticals has a 1 year low of $1.58 and a 1 year high of $3.84. The stock has a market capitalization of $66.45 million, a PE ratio of -0.89 and a beta of 1.97. The company has a 50 day moving average price of $1.94 and a two-hundred day moving average price of $2.44.

NRx Pharmaceuticals (NASDAQ:NRXP) last released its quarterly earnings results on Monday, March 23rd. The company reported $0.19 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.28. The firm had revenue of $0.98 million for the quarter, compared to the consensus estimate of $7.53 million. Sell-side analysts expect that NRx Pharmaceuticals will post -1.75 EPS for the current fiscal year.

Institutional Investors Weigh In On NRx Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. One Wealth Management Investment & Advisory Services LLC increased its holdings in NRx Pharmaceuticals by 35.3% during the 4th quarter. One Wealth Management Investment & Advisory Services LLC now owns 37,873 shares of the company’s stock worth $103,000 after acquiring an additional 9,882 shares during the period. State Street Corp increased its holdings in shares of NRx Pharmaceuticals by 14.0% in the fourth quarter. State Street Corp now owns 86,984 shares of the company’s stock worth $236,000 after purchasing an additional 10,700 shares during the period. Ethos Financial Group LLC bought a new position in shares of NRx Pharmaceuticals in the third quarter worth $39,000. Sjbenen Advisory LLC purchased a new stake in shares of NRx Pharmaceuticals in the fourth quarter worth $41,000. Finally, Two Sigma Investments LP raised its position in shares of NRx Pharmaceuticals by 66.4% in the third quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock worth $173,000 after buying an additional 20,880 shares in the last quarter. 4.27% of the stock is currently owned by institutional investors.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.